• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ST. JUDE MEDICAL, INC. (CS-WOODRIDGE) TRIFECTA STENTED TISSUE VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ST. JUDE MEDICAL, INC. (CS-WOODRIDGE) TRIFECTA STENTED TISSUE VALVE; HEART-VALVE, NON-ALLOGRAFT TISSUE Back to Search Results
Device Problems Backflow (1064); Gradient Increase (1270); Obstruction of Flow (2423)
Patient Problems Atrial Fibrillation (1729); Regurgitation (2259); Stenosis (2263); Complete Heart Block (2627)
Event Type  Injury  
Manufacturer Narrative
As reported in a research article, five patients had a valve-in-valve performed to replace a trifecta valve due to stenosis, regurgitation, and high gradient.The results of the investigation are inconclusive since a valve-in-valve was performed and the device was not accessible for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.
 
Event Description
It was reported through a research article identifying trifecta that may be related to a valve in valve procedure.Specific patient information is documented as unknown.Details are listed in the article, titled [valve-in-valve implantation using the acurate neo in degenerated aortic bioprostheses].It was reported from the study that 85 patients from 14 centers in europe and (b)(6) were implanted with a variety of make and model of tissue heart valves.Five of the patients were originally implanted with a trifecta valve.After a median time of 9.2 years (range 1.1 to 18.1 years), stenosis, regurgitation, and high gradient were observed and the patients were treated with valve in valve procedure using the acurate neo.The major complications for the 30-day outcomes were reported to be vascular complication (5%), bleeding (5%), kidney injury (2%), permanent pacemaker implantation (1%), left bundle branch block (2%), new onset atrial fibrillation (2%), and stroke (1%).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
TRIFECTA STENTED TISSUE VALVE
Type of Device
HEART-VALVE, NON-ALLOGRAFT TISSUE
Manufacturer (Section D)
ST. JUDE MEDICAL, INC. (CS-WOODRIDGE)
177 east county road b
st. paul MN 55117
Manufacturer (Section G)
ST. JUDE MEDICAL, INC. (CS-WOODRIDGE)
177 east county road b
st. paul MN 55117
Manufacturer Contact
pamela yip
5050 nathan lane n
plymouth, MN 55442
6517565400
MDR Report Key9482181
MDR Text Key171661651
Report Number3007113487-2019-00040
Device Sequence Number1
Product Code LWR
Combination Product (y/n)N
Reporter Country CodeSZ
PMA/PMN Number
P100029
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional,l
Reporter Occupation Physician
Type of Report Initial
Report Date 12/17/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/17/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received11/20/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
-
-